Chronic Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Chronic pain is a common, complex, and distressing problem that significantly impacts society and individuals. It commonly arises as a consequence of injury or disease. Many pain categories and types exist, encompassing neuropathic, nociceptive, musculoskeletal, inflammatory, psychogenic, and mechanical pain. Risk factors have been classified into “modifiable” and “non-modifiable.” The primary clinical risk factor for chronic pain development is the coexistence of acute or chronic pain at other bodily sites. The likelihood of chronic pain increases in proportion to the severity and number of these sites. Painful stimuli prompt alterations in brain chemistry that predispose individuals to chronic pain. This heightened susceptibility can manifest within days of continuous exposure to painful stimuli and persist for up to a year after pain resolution. Both having multiple causes of chronic pain and enduring pain for extended periods are associated with diminished quality of life. The differential diagnosis for generalized chronic pain encompasses patients experiencing allodynia due to chronic opioid use and those afflicted with major depressive disorder, as well as individuals with other psychiatric or sleep disorders like insomnia. Pharmacological therapies for chronic pain involve nonopioid analgesics such as nonsteroidal anti-inflammatories (NSAIDs), acetaminophen, and aspirin. Additionally, medications like tramadol, opioids, antiepileptic drugs (e.g., gabapentin or pregabalin) are employed. Moreover, antidepressants such as tricyclic antidepressants and selective serotonin-norepinephrine reuptake inhibitors (SNRIs), topical analgesics, muscle relaxants, N-methyl-D-aspartate (NMDA) receptor antagonists, and alpha-2 adrenergic agonists are utilized as pharmacological interventions.
• In the USA, an estimated 20.9% of U.S. adults experienced chronic pain,the estimated prevalence of high-impact chronic pain (6.9%). Further, the age-adjusted prevalence of high-impact chronic pain in was 6.4%.

Thelansis’s “Chronic Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Pain treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Chronic Pain across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Chronic Pain Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Chronic Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Chronic Pain, Chronic Pain market outlook, Chronic Pain competitive landscape, Chronic Pain market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)